Special Issue "SARS-CoV-2: Immunopeptidomics and Other Immunological Studies"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 7630
Interests: biochemistry, genetics and molecular biology immunology and microbiology medicine chemistry chemical engineering pharmacology, toxicology and pharmaceutics agricultural and biological sciences neurosc
Interests: immunology; inflammation; vaccine formulations; vaccine validations; biologics; immunotherapeutics; antigen delivery; infectious diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue in Vaccines: Vaccines for Infectious and Chronic Diseases 2.0
Special Issue in Vaccines: Management Strategies of Recent Viral Disease Outbreaks: Progress and Challenges
Topics: Inflammation: The Cause of All Diseases
Topics: Inflammation: The Cause of all Diseases 2.0
Since the beginning of the pandemic, new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged which have the ability to influence the airborne transmission, virulence, and immune evasion of affected individuals. The neutralizing antibodies produced as a result of vaccination or post recovery from COVID-19 do not provide sufficient immune protection against emerging SARS-CoV-2 variants. A better strategy would be to design SARS-CoV-2 variant-specific vaccines to gain better insights into their safety and efficacy. Recent quantum leaps in mass spectrometry (MS) and data processing have considerably benefited immunoproteomics as a group of methods that facilitate the identification of antigenic peptides or proteins. Immunopeptidomics is a kind of immunoproteomic technology that allows for the antibody-independent identification of antigens. Immunopeptidomics seeks to identify antigens as peptides presented on cell surfaces by major histocompatibility complexes (MHCs), also known as immunopeptides, MHC-associated peptides, and MHC ligands. This method, along with other immunological studies, can be redirected for the development of novel diagnostic tools as well as vaccines.
It is time to welcome contributions for this Special Issue titled “SARS-CoV-2: Immunopeptidomics and Other Immunological Studies.” The goal is to provide comprehensive information on all aspects of research related to the immunological studies of SARS-CoV-2 and immunopeptidomics for vaccine development.
This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, short communications) on immunopeptidomics and other immunological studies regarding SARS-CoV-2. We welcome the submission of both basic and applied research papers that aim to improve the understanding of the immune response against SARS-CoV-2, as well as the short- and long-term effects of host immune responses to SARS-CoV-2.
We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and to discover together the means to overcome the pandemic.
This Special Issue is especially dedicated for the 75th Year celebration of L M College of Pharmacy, Ahmedabad (India).
Prof. Dr. Elrashdy M. Redwan
Dr. Vivek P. Chavda
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immunological studies
- tracking the viral antigenic shift associated with the different viral variants
- viral antigen exploration
- MHC/HLA-viral antigen processing, presentation and the potency of the associated immune response
- the role of Fc gamma subtypes in the proper and durable immune response versus wane
- mass spectrometry
- viral proteomics, vaccine platforms, and vaccinations
- whole-virus vaccines and analysis of proteome changes during Vero culturing and propagation
- adaptive immunity post infection and/or vaccination
- T- and B-cell immune responses induction and durability
- viral macromolecules circulation, prevalence, and shedding associated with pathogenesis and/or post-COVID-19 syndromes